TC
XERS icon

Truvestments Capital’s Xeris Biopharma Holdings XERS Stock Holding History

Truvestments Capital’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.1K Hold
8,118
– – 0.01% 510
2025
Q4 		$63.7K Buy
8,118
+3,979
+96% +$31.3K 0.01% 410
2025
Q3 		$33.7K Buy
4,139
+566
+16% +$3.76K 0.01% 498
2025
Q2 		$16.7K Buy
+3,573
New +$16.4K ﹤0.01% 567
2025
Q1 		– Sell
-847
Closed -$2.87K – 1165
2024
Q4 		$2.87K Buy
+847
New +$2.72K ﹤0.01% 779

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Truvestments Capital's XERS Position: Q1 2026 in Review

Truvestments Capital held its Xeris Biopharma Holdings (XERS) position steady in Q1 2026 at 8,118 shares worth $47.1K. The position accounts for 0.01% of the portfolio, ranked #510.

Truvestments Capital first reported a position in XERS in Q4 2024 and has held it in 5 quarters since. The position peaked at $63.7K in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Truvestments Capital held 8,118 shares of Xeris Biopharma Holdings worth $47.1K as of Q1 2026.
  • Truvestments Capital left its Xeris Biopharma Holdings share count unchanged in Q1 2026.
  • Xeris Biopharma Holdings made up 0.01% of Truvestments Capital's portfolio in Q1 2026, its #510 holding.
  • Truvestments Capital first reported a position in Xeris Biopharma Holdings in Q4 2024 and has held it in 5 quarters since.
  • Truvestments Capital's Xeris Biopharma Holdings position peaked at $63.7K in Q4 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.